A DRUG-DRUG INTERACTION STUDY TO EVALUATE THE EFFECT OF VADADUSTAT ON THE PHARMACOKINETICS OF CELECOXIB, A CYP2C9 SUBSTRATE IN HEALTHY VOLUNTEERS

被引：0
|
作者：
Chandorkar, Gurudatt A. [1 ]
Farzaneh-Far, Ramin [2 ]
Buch, Akshay [1 ]
Maroni, Bradley [2 ]
机构：
[1] Akebia Therapeut, Clin Pharmacol, Cambridge, MA USA
[2] Akebia Therapeut, Med Res, Cambridge, MA USA
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2016年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
SP322
引用
收藏
页码：197 / 197
页数：1
相关论文
共 50 条
  • [1] Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects
    Katsuyuki Murase
    Lucy Lee
    Jiyuan Ma
    Rosemary Barrett
    Martin Thoolen
    European Journal of Clinical Pharmacology, 2022, 78 : 1823 - 1831
  • [2] Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects
    Murase, Katsuyuki
    Lee, Lucy
    Ma, Jiyuan
    Barrett, Rosemary
    Thoolen, Martin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (11) : 1823 - 1831
  • [3] Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug-drug interaction studies for CYP2C9
    Klein, Kerenaftali
    Gueorguieva, Ivelina
    Aarons, Leon
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (02) : 147 - 160
  • [4] Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele
    Shimamoto, J
    Ieiri, I
    Urae, A
    Kimura, M
    Irie, S
    Kubota, T
    Chiba, K
    Ishizaki, T
    Otsubo, K
    Higuchi, S
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (01) : 65 - 68
  • [5] Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele
    J. Shimamoto
    I. Ieiri
    A. Urae
    M. Kimura
    S. Irie
    T. Kubota
    K. Chiba
    T. Ishizaki
    K. Otsubo
    S. Higuchi
    European Journal of Clinical Pharmacology, 2000, 56 : 65 - 68
  • [6] Effect of CYP2C9 genotype on the pharmacokinetics of celecoxib.
    Gelmann, A
    Tang, C
    Rodrigues, AD
    Schwartz, JI
    Rushmore, T
    Waldman, SA
    Greenberg, HE
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P27 - P27
  • [7] In vitro assessment of drug-drug interaction potential between CYP2C9 substrates and cannabinoids
    Lessard, E
    Gauvin, C
    Morin, PE
    Grudé, P
    Ducharme, J
    DRUG METABOLISM REVIEWS, 2005, 37 : 40 - 41
  • [8] EFFECT OF CYP2C8 AND CYP2C9 AND GENDER ON PIOGLITAZONE PHARMACOKINETICS IN HEALTHY VOLUNTEERS
    Roman, M.
    Ochoa, M. D.
    Talegon, M.
    Rivas, A.
    Prieto, R.
    Cabaleiro, T.
    Abad, F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2013, 113 : 23 - 23
  • [9] A PHARMACOKINETIC/PHARMACODYNAMIC DRUG-DRUG INTERACTION OF AVATROMBOPAG WHEN COADMINISTERED WITH DUAL OR NON-DUAL CYP2C9 AND CYP3A PERPETRATORS TO HEALTHY VOLUNTEERS.
    Nomoto, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S82 - S82
  • [10] Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6
    Bahar, Muh Akbar
    Setiawan, Didik
    Hak, Eelko
    Wilffert, Bob
    PHARMACOGENOMICS, 2017, 18 (07) : 701 - 743
12345